<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04403256</url>
  </required_header>
  <id_info>
    <org_study_id>2019-11-054-001</org_study_id>
    <nct_id>NCT04403256</nct_id>
  </id_info>
  <brief_title>Bone-biomarkers of Spinal Cord Injury Patients</brief_title>
  <official_title>Changes of Bone-biomarker According to the Severity of Spinal Cord Injury.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yeungnam University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yeungnam University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with spinal cord injury have a high prevalence of osteoporosis due to chronic
      skeletal unloading. Recently, various treatment drugs for osteoporosis have been developed.
      In particular, romosozumab, a sclerostin inhibitor, has been reported to have a high
      therapeutic effect as an inhibitor of bone resorption while promoting bone formation.
      However, there are a few research concerning sclerostin of spinal cord injuries patients.
      Therefore we want to analyze the change of sclerostin as well as factors indicating bone
      formation and absorption marker in spinal cord injury patient.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 5, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Serum sclerostin level</measure>
    <time_frame>1 year</time_frame>
    <description>Serum sclerostin level in spinal cord injury patients</description>
  </primary_outcome>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Spinal Cord Injuries</condition>
  <condition>Bone Resorption</condition>
  <condition>Osteoporosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with spinal cord injury difficult to walk
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  spinal cord injury patients

          -  Functional ambulatory category index of 3 or less

        Exclusion Criteria:

          -  history of using bone absorption medication within the effective period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Yeungnam University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>42415</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong gyu Lee, M.D., Ph.D.</last_name>
      <phone>82536203829</phone>
      <email>painfree@yu.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 25, 2020</study_first_submitted>
  <study_first_submitted_qc>May 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2020</study_first_posted>
  <last_update_submitted>May 25, 2020</last_update_submitted>
  <last_update_submitted_qc>May 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yeungnam University Hospital</investigator_affiliation>
    <investigator_full_name>Dong Gyu Lee</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <keyword>Sclerostin</keyword>
  <keyword>osteoporosis</keyword>
  <keyword>Spinal cord injury</keyword>
  <keyword>Unloading</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Bone Resorption</mesh_term>
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

